Literature DB >> 16417067

Medications for migraine prophylaxis.

Seema Modi1, Dionne M Lowder.   

Abstract

Sufficient evidence and consensus exist to recommend propranolol, timolol, amitriptyline, divalproex, sodium valproate, and topiramate as first-line agents for migraine prevention. There is fair evidence of effectiveness with gabapentin and naproxen sodium. Botulinum toxin also has demonstrated fair effectiveness, but further studies are needed to define its role in migraine prevention. Limited evidence is available to support the use of candesartan, lisinopril, atenolol, metoprolol, nadolol, fluoxetine, magnesium, vitamin B2 (riboflavin), coenzyme Q10, and hormone therapy in migraine prevention. Data and expert opinion are mixed regarding some agents, such as verapamil and feverfew; these can be considered in migraine prevention when other medications cannot be used. Evidence supports the use of timed-release dihydroergotamine mesylate, but patients should be monitored closely for adverse effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16417067

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  15 in total

1.  Alkali replacement raises urinary citrate excretion in patients with topiramate-induced hypocitraturia.

Authors:  R Allan Jhagroo; Margaret L Wertheim; Kristina L Penniston
Journal:  Br J Clin Pharmacol       Date:  2015-12-10       Impact factor: 4.335

2.  Non-steroidal anti-inflammatory drugs in athletes.

Authors:  G Lippi; M Franchini; G C Guidi; W F Kean
Journal:  Br J Sports Med       Date:  2006-08       Impact factor: 13.800

3.  Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer.

Authors:  Anniina Koski; Mari Raki; Petri Nokisalmi; Ilkka Liikanen; Lotta Kangasniemi; Timo Joensuu; Anna Kanerva; Sari Pesonen; Ramon Alemany; Akseli Hemminki
Journal:  Mol Ther       Date:  2011-11-01       Impact factor: 11.454

Review 4.  OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.

Authors:  James E Frampton
Journal:  Drugs       Date:  2012-04-16       Impact factor: 9.546

5.  Prophylactic treatment of migraine by GPs: a qualitative study.

Authors:  Frans Dekker; Arie Knuistingh Neven; Boukje Andriesse; David Kernick; Michel D Ferrari; Willem J J Assendelft
Journal:  Br J Gen Pract       Date:  2012-04       Impact factor: 5.386

Review 6.  Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives.

Authors:  Adriana A Garcia; Ana Koperniku; Julio C B Ferreira; Daria Mochly-Rosen
Journal:  Trends Pharmacol Sci       Date:  2021-08-10       Impact factor: 17.638

Review 7.  Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life.

Authors:  Dawn C Buse; Marcia F T Rupnow; Richard B Lipton
Journal:  Mayo Clin Proc       Date:  2009-05       Impact factor: 7.616

8.  β-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study.

Authors:  Kasper Meidahl Petersen; Espen Jimenez-Solem; Jon Traerup Andersen; Morten Petersen; Kasper Brødbæk; Lars Køber; Christian Torp-Pedersen; Henrik Enghusen Poulsen
Journal:  BMJ Open       Date:  2012-07-19       Impact factor: 2.692

9.  Renin angiotensin system: A novel target for migraine prophylaxis.

Authors:  Ruchika Nandha; Harpal Singh
Journal:  Indian J Pharmacol       Date:  2012-03       Impact factor: 1.200

10.  Patient outcome in migraine prophylaxis: the role of psychopharmacological agents.

Authors:  Maurizio Pompili; Gianluca Serafini; Marco Innamorati; Giulia Serra; Giovanni Dominici; Juliana Fortes-Lindau; Monica Pastina; Ludovica Telesforo; David Lester; Paolo Girardi; Roberto Tatarelli; Paolo Martelletti
Journal:  Patient Relat Outcome Meas       Date:  2010-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.